Total trials
188
Active
39
Phase 3
1
Total enrollment
29,688
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Gemcitabine Hydrochloride combined with continuous saline irrigation | — | — | — | — | — | 1 | |
| Epirubicin Hydrochloride combined with continuous saline irrigation | — | — | — | — | — | 1 | |
| ultra early physiotherapy intervention | — | — | — | — | — | 1 |
Next readouts
- 2025-10
- 2025-10-30
Top conditions
- Body Composition9
- Oxidative Stress8
- Skeletal Muscle Damage7
- Muscle Damage6
- Energy Expenditure6
- Resting Metabolic Rate6
- Cerebral Palsy5
- Chronic Pain5
Frequently asked questions about University of Thessaly
- How many clinical trials does University of Thessaly have on ClinicalTrials.gov?
- University of Thessaly is listed as the lead sponsor on 188 clinical trials in ClinicalTrials.gov, 39 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Thessaly's trials are in Phase 3?
- 1 of University of Thessaly's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does University of Thessaly focus on?
- University of Thessaly's most-studied conditions on ClinicalTrials.gov are Body Composition, Oxidative Stress, Skeletal Muscle Damage, Muscle Damage, Energy Expenditure.
- When are University of Thessaly's next clinical trial readouts?
- University of Thessaly has 2 upcoming primary-completion readouts tracked here; the soonest is “Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline)”, expected around 2025-10.